Author

Olga Boix

Observed name: O. Boix

Institutions: MedSIR (Spain), Vall d'Hebron Institute of Oncology

Observed institutions: MedSIR (Spain), Centro de Investigacion Principe Felipe, Vall d'Hebron Institute of Oncology

ORCID: 0000-0002-3223-5723

Observed ORCID: 0000-0002-3223-5723

OpenAlex ID: A5034911376

Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

2022 · Inés Marín, Olga Boix, et al. · Cancer Discovery · 374

PDF

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

2024 · Selim Chaib, José Alberto López-Domínguez, et al. · Nature Cancer · 126

PDF

pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation

2022 · Olga Boix, Marion Martinez, et al. · Nature Communications · 57

PDF

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

2025 · María Gion, Isabel Blancas, et al. · Nature Medicine · 40

PDF

Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study

2025 · Antonio Calles, Alejandro Navarro, et al. · Journal of Thoracic Oncology · 17

PDF

microRNA-mediated differential expression of TRMU, GTPBP3 and MTO1 in cell models of mitochondrial-DNA diseases

2017 · Salvador Meseguer, Olga Boix, et al. · Scientific Reports · 16

PDF

A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study

2026 · L. Garrigós, M. Ruiz-Borrego, et al. · Annals of Oncology · 5

PDF

Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.

2024 · Elena Lopez-Miranda, José Manuel Pérez García, et al. · Journal of Clinical Oncology · 4

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial

2025 · Elena López-Miranda, Jose Manuel Pérez-García, et al. · Breast Cancer Research · 3

PDF

ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (ELA) + everolimus (EVE) versus ELA + placebo (PBO) in ER+/HER2- advanced breast cancer (aBC) patients with ESR1 -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.

2025 · Antonio Llombart-Cussac, Jose Manuel Perez-Garcia, et al. · Journal of Clinical Oncology · 2

Abstract PS1-11-02: The ADELA study: a double-blind, placebo-controlled, randomized phase 3 trial of elacestrant + everolimus versus elacestrant + placebo in ER+/HER2- advanced breast cancer (ABC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i

2026 · A. Llombart-Cussac, J. M. Pérez-García, et al. · Clinical Cancer Research · 1

Supplementary Table S1 from Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

2023 · Ines Marin, Olga Boix, et al. · 1

Data from Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

2023 · Ines Marin, Olga Boix, et al. · 1

Data from Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

2023 · Ines Marin, Olga Boix, et al. · 1

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

2026 · José Manuel Pérez-García, Antonio Llombart-Cussac, et al. · Future Oncology

PDF

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

2026 · José Manuel Pérez-García, Antonio Llombart-Cussac, et al. · Figshare

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

2026 · Selim Chaib, José Alberto López-Domínguez, et al. · Nature Cancer

PDF

ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2− advanced breast cancer (aBC) patients with ESR1 -mutated tumors progressing on endocrine therapy (ET) + CDK4/6i.

2026 · Antonio Llombart-Cussac, José Manuel Pérez García, et al. · Journal of Clinical Oncology

214O Chemotherapy-free, pathological complete response (pCR)-guided strategy with trastuzumab-pertuzumab (HP) and T-DM1 in HER2+ early breast cancer (EBC): PHERGain-2

2026 · L. Garrigós, M. Ruiz Borrego, et al. · ESMO Open

Abstract CT226: ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant (Ela) + everolimus (EVE) versus elacestrant + placebo in ER+/HER2- advanced breast cancer (aBC) patients with ESR1-mutated tumors progressing on endocrine therapy (ET) + CDK4/6i

2026 · Antonio Llombart-Cussac, José Manuel Pérez-García, et al. · Cancer Research

Supplementary Table S1 from Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity